HLS Therapeutics Inc.

TSX:HLS Stock Report

Market Cap: CA$102.1m

HLS Therapeutics Valuation

Is HLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLS (CA$3.21) is trading below our estimate of fair value (CA$21.71)

Significantly Below Fair Value: HLS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLS?

Key metric: As HLS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HLS. This is calculated by dividing HLS's market cap by their current revenue.
What is HLS's PS Ratio?
PS Ratio1.3x
SalesUS$56.94m
Market CapUS$73.08m

Price to Sales Ratio vs Peers

How does HLS's PS Ratio compare to its peers?

The above table shows the PS ratio for HLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
RX BioSyent
3.7x12.0%CA$126.5m
AYR.A Ayr Wellness
0.2x2.6%CA$115.0m
IAN iAnthus Capital Holdings
0.3xn/aCA$66.7m
HASH Simply Solventless Concentrates
6.6xn/aCA$51.3m
HLS HLS Therapeutics
1.3x7.1%CA$102.1m

Price-To-Sales vs Peers: HLS is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does HLS's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

31 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.6%US$82.37m
IAN iAnthus Capital Holdings
0.3xn/aUS$47.79m
DB Decibel Cannabis
0.3x11.8%US$20.60m
TIUM.U Cansortium
0.3xn/aUS$28.70m
HLS 1.3xIndustry Avg. 0.7xNo. of Companies31PS01.22.43.64.86+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HLS is expensive based on its Price-To-Sales Ratio (1.3x) compared to the Canadian Pharmaceuticals industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is HLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: HLS is expensive based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$3.21
CA$5.71
+78.0%
44.6%CA$9.52CA$3.50n/a5
Nov ’25CA$3.25
CA$6.08
+87.1%
45.8%CA$9.55CA$3.27n/a4
Oct ’25CA$3.66
CA$5.64
+54.2%
46.3%CA$9.51CA$3.25n/a5
Sep ’25CA$3.32
CA$5.64
+70.0%
46.3%CA$9.51CA$3.25n/a5
Aug ’25CA$3.14
CA$5.93
+88.8%
41.6%CA$9.66CA$3.75n/a5
Jul ’25CA$3.35
CA$5.85
+74.6%
41.4%CA$9.51CA$3.75n/a5
Jun ’25CA$3.72
CA$5.85
+57.3%
41.4%CA$9.51CA$3.75n/a5
May ’25CA$4.65
CA$6.83
+47.0%
39.0%CA$10.70CA$4.23n/a5
Apr ’25CA$4.06
CA$7.23
+78.2%
37.4%CA$10.51CA$4.16n/a4
Mar ’25CA$4.20
CA$7.55
+79.8%
31.0%CA$10.25CA$4.35n/a4
Feb ’25CA$4.15
CA$7.18
+73.1%
30.7%CA$10.21CA$5.02n/a3
Jan ’25CA$3.95
CA$8.16
+106.6%
31.7%CA$11.19CA$5.00n/a4
Dec ’24CA$3.44
CA$8.37
+143.4%
32.3%CA$11.53CA$5.01n/a4
Nov ’24CA$4.93
CA$12.25
+148.4%
15.5%CA$14.27CA$9.20CA$3.254
Oct ’24CA$5.00
CA$12.11
+142.1%
15.5%CA$14.06CA$9.06CA$3.664
Sep ’24CA$4.67
CA$12.83
+174.7%
17.6%CA$15.02CA$9.09CA$3.324
Aug ’24CA$6.10
CA$13.86
+127.2%
22.9%CA$17.86CA$8.99CA$3.144
Jul ’24CA$5.76
CA$15.79
+174.1%
27.5%CA$22.71CA$9.75CA$3.355
Jun ’24CA$4.34
CA$16.71
+285.1%
25.9%CA$23.40CA$10.05CA$3.725
May ’24CA$5.51
CA$17.87
+224.4%
15.9%CA$23.12CA$14.61CA$4.655
Apr ’24CA$6.30
CA$18.23
+189.4%
16.0%CA$23.71CA$14.98CA$4.065
Mar ’24CA$8.53
CA$23.31
+173.3%
6.7%CA$25.97CA$21.69CA$4.205
Feb ’24CA$9.59
CA$23.22
+142.1%
6.6%CA$25.85CA$21.61CA$4.155
Jan ’24CA$9.83
CA$23.66
+140.7%
5.9%CA$25.92CA$22.16CA$3.955
Dec ’23CA$9.95
CA$23.34
+134.5%
6.0%CA$25.63CA$21.84CA$3.445
Nov ’23CA$9.96
CA$26.05
+161.5%
12.0%CA$32.03CA$23.24CA$4.935

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.38

7D

-10.5%

1Y

-59.6%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.11

7D

3.4%

1Y

37.9%

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$5.69

7D

-5.8%

1Y

-51.2%